logo

Biocryst Pharmaceuticals Inc (BCRX)



Trade BCRX now with
  Date
  Headline
3/2/2021 7:15:34 AM BioCryst Submits MAA To UK’s MHRA Seeking Approval Of ORLADEYO To Prevent Attacks In Patients With Hereditary Angioedema
2/3/2021 7:20:34 AM BioCryst Says FDA Approved Supplemental New Drug Application For RAPIVAB
1/22/2021 7:04:42 AM BioCryst Secures Approval Of ORLADEYO In Japan
12/22/2020 7:08:23 AM Amended: BioCryst Expects NIAID To Discontinue Pursuit Of A COVID-19 Indication For Galidesivir
12/21/2020 7:22:16 AM BioCryst Announces Positive Phase 1 Results With BCX9250 For Treatment Of Fibrodysplasia Ossificans Progressiva
12/16/2020 7:12:03 AM BioCryst Says ORLADEYO Is Now Available For Shipment To Patients With A Prescription In US
12/3/2020 8:52:31 PM BioCryst FDA Oks ORLADEYO, Oral, Once-daily Therapy To Prevent Attacks In Hereditary Angioedema Patients
11/13/2020 7:14:32 AM BioCryst Presents New Clinical Data On Berotralstat In APeX-2 Trial